• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Repare Therapeutics Inc. - Common Shares (NQ: RPTX )

    1.180 -0.020 (-1.67%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 103,625
    Open 1.220
    Bid (Size) 1.130 (5)
    Ask (Size) 1.300 (8)
    Prev. Close 1.200
    Today's Range 1.150 - 1.220
    52wk Range 1.060 - 7.450
    Shares Outstanding 42,088,446
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
    From Repare Therapeutics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -10.61%
    -10.61%
    1 Month
    +2.61%
    +2.61%
    3 Month
    -64.02%
    -64.02%
    6 Month
    -59.45%
    -59.45%
    1 Year
    -83.02%
    -83.02%

    More News

    Read More
    Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
    Via Benzinga
    Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast
    Via Benzinga
    Exposures Fossil Fuels
    Why Is Repare Therapeutics Stock Trading Lower On Friday?
    Via Benzinga
    Exposures Product Safety
    US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings
    Via Benzinga
    US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
    From Repare Therapeutics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
    From Repare Therapeutics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Participate in Two Upcoming Investor Conferences
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
    From Repare Therapeutics Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.